2017 News Releases

Keyword Search
 
DateTitle  
03/21/17Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting
Proprietary Axillary Sweating Daily Diary patient-reported outcome instrument developed with feedback from FDA MENLO PARK, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today presented new information about the Axillary Sweating Daily Diary (ASDD), a proprietary patient-... 
 Printer Friendly Version
03/17/17Dermira to Highlight Data for Three Clinical Programs at Annual Maui Derm Meeting
New data for the Axillary Sweating Daily Diary patient-reported outcome instrument from the glycopyrronium tosylate Phase 2 trial in primary axillary hyperhidrosis to be highlighted Additional data from the CIMPACT Phase 3 trial of CIMZIA® (certolizumab pegol) in patients with moderate-to-severe psoriasis will be presented MENLO PARK, Calif., March 17, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical der... 
 Printer Friendly Version
03/07/17Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it has closed its previously announced public offering of 5,750,000 shares of its common stock, including 750,000 shares sold upon full exercise of the underwriters’ option to purchase addition... 
 Printer Friendly Version
03/04/17New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual Meeting
Late-breaking, investigational 16-week data presented from the CIMPASI-1 and CIMPASI-2 trials showing CIMZIA demonstrated statistically and clinically significant improvements for patients with moderate-to-severe chronic plaque psoriasis Four-year data from the CIMZIA RAPID-PSA study showing long-term maintenance of improvement in the joint and skin manifestations of psoriatic arthritis regardless of prior exposure to an anti-TNF, or as monotherapy without concomitant use of disease modifyi... 
 Printer Friendly Version
03/03/17Dermira Presents New Data in Primary Axillary Hyperhidrosis and Acne at American Academy of Dermatology 2017 Annual Meeting
Data from glycopyrronium tosylate Phase 3 program and olumacostat glasaretil Phase 2 trial show patients experienced early and sustained clinical effects with each treatment ORLANDO, Fla., March 03, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced new data, from its glycopyrr... 
 Printer Friendly Version
03/02/17Dermira to Present at Cowen and Company 37th Annual Health Care Conference
MENLO PARK, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 4:00 p.m. ET (1:00 p.m. PT)... 
 Printer Friendly Version
03/01/17Dermira Prices $168.5 Million Public Offering of Common Stock
MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the pricing of its underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $33.70 per share. The gross proceeds to Dermira from the offering, before deductin... 
 Printer Friendly Version
02/28/17Dermira Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it intends to offer 3,700,000 shares of its common stock in an underwritten public offering. Dermira also expects to grant to the underwriters a 30-day option to purchase up to 555,000 additiona... 
 Printer Friendly Version
02/28/17Dermira Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
-- Planned submission of NDA for glycopyrronium tosylate (formerly DRM04) in 2H17 on schedule after pre-NDA meeting with FDA -- -- Management to host webcast and conference call today 4:30 p.m. ET / 1:30 p.m. PT -- MENLO PARK, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions... 
 Printer Friendly Version
02/27/17Dermira Data from DRM04 and Olumacostat Glasaretil Clinical Programs to Be Presented at American Academy of Dermatology Annual Meeting
MENLO PARK, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from its DRM04 and olumacostat glasaretil (formerly DRM01) clinical programs will be presented during poster sessions at the 75th Annual Meeting of the American Academy of Dermatology (AAD) being held in Or... 
 Printer Friendly Version
02/22/17Dermira to Report Fourth Quarter and Full Year 2016 Financial Results
Management to Host Webcast and Conference Call on February 28, 2017 at 4:30 p.m. ET MENLO PARK, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will report fourth quarter and full year 2016 financial results after the close of U.S. financial markets on February 28, 2... 
 Printer Friendly Version
02/08/17Dermira to Present at Leerink Partners 6th Annual Global Healthcare Conference
MENLO PARK, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. DERM, a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Leerink Partners 6th Annual Global Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 1:30 p.m. ET (10:30 a.m. PT) on Wednesday, February ... 
 Printer Friendly Version
01/19/17Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trials Submission of marketing applications to regulatory authorities expected in third quarter of 2017 BRUSSELS, Belgium and MENLO PARK, Calif., Jan. 19, 2017 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced key results from CIMPACT, a Phase 3, multi-center, placebo-controlled and active-controlled clinical trial evaluating the efficacy and safety of CIMZIA® (certolizumab pe... 
 Printer Friendly Version
01/06/17Dermira Provides Corporate Update
Treatment period for DRM04 ARIDO trial completed Phase 3 acne clinical program for olumacostat glasaretil initiated Topline data for third and final CIMZIA® (certolizumab pegol) Phase 3 trial expected first quarter of 2017 Chief Commercial Officer appointed MENLO PARK, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of... 
 Printer Friendly Version
01/05/17Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
Previously served at Allergan as a Vice President for Sales & Marketing, member of Operational Leadership Team Worked on several leading dermatology brands including ACZONE® and BOTOX® during 15-year career at Allergan MENLO PARK, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, t... 
 Printer Friendly Version
01/04/17Dermira Elects Emmanuel Caeymaex to Board of Directors
Currently Executive Vice President, Immunology Patient Value Unit Head at UCB S.A. MENLO PARK, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the election of Emmanuel Caeymaex, Executive Vice President, Immunology Patient Value Unit Head at UCB S.A., to its board of directo... 
 Printer Friendly Version
01/03/17Dermira Initiates Phase 3 Clinical Program in Acne
First patients dosed in Phase 3 program evaluating olumacostat glasaretil, a novel topical molecule, in patients with acne vulgaris Two Phase 3 trials expected to enroll a total of 1,400 patients Topline results expected in the first half of 2018 MENLO PARK, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with... 
 Printer Friendly Version